This is not an exhaustive list of questions or statements to consider for your collaborative practice agreement, but is intended to guide your development of the collaborative practice agreement for your practice. A nurse practitioner could make a combination of the above or use another approach to describe in the collaborative practice agreement the prescribing authority for the nurse practitioner. It is necessary to describe in the collaborative practice agreement, the drugs and devices that can be prescribed by the nurse practitioner in any practice site, as described in Rule 21 NCAC32M.0109 “prescription authority” and in the Board of Directors of Law 21 NCAC36.0809 “prescription authority”. How will you proceed with the new rules for prescribing and dispensing drugs and devices that are not included in the agreement on cooperative practice under Rule 21 NCAC366.0809 (b) (3) (A) (B) and 21 NCAC32M.0109 (b) (3) (A) (B)? How will your minimum standards for consultation between you as a nurse and your primary supervisory physician be applied, as described at 21 HAC 36.0810 (e) (1) (A) (A) (B) (B) (B) (2) (A) (C) and 21 HAC 32M (e) (1) (A)-:2) (A) (3)). This nurse practitioner/doctor counsel will be different for the new graduate, new nurse practitioner with the first authorization to practice in North Carolina compared to a collaborative practice agreement later approved by a nurse practitioner previously to practice in North Carolina and another primary supervisory physician. What will be your process, developed by the nurse and primary supervisor for the ongoing review of care at each training site, including a written plan to assess the quality of care provided for one or more common clinical problems? What medications and devices will you prescribe in each place of exercise? You can list certain drugs or certain categories of drugs. A complete description of the categories of drugs and devices to treat common health problems in your particular practice can be developed. For example: categories of drugs, such as anti-Semitic drugs, hypoglycemics-oral/insulin, oral hormones and contraceptives, cephalosporins, aminoglycosides, antivirals, antiasthmatics, diuretics, antihypertensivus, etc. may be indicated. Exceptions may be granted by classes of drugs or certain drugs in a class or administration routes. Rules 21NCAC36.0810 (b) (1) (2) and 21 NCAC32M.0110(b) (1) (2) “Quality Assurance Standards for a Collaborative Practice Agreement” conclude and maintain the agreement on collaborative practice by both the primary physician and the specialist and maintained at each place of practice.